| Code | Display | Definition |
| DE1 | Target age 35 for HPV screening | First binding age at which a woman becomes a target for primary HPV high-risk DNA screening per Mongolia MOH Order A/641 (2020) section 2.2 (HPV-test-capable facilities). |
| DE2 | Target age 45 for HPV screening | Second binding age at which a woman becomes a target for primary HPV high-risk DNA screening per Mongolia MOH Order A/641 (2020) section 2.2 (HPV-test-capable facilities). |
| DE3 | HPV high-risk DNA test | A laboratory test that detects high-risk human papillomavirus DNA from a cervical sample. The careHPV test (used in the April 2026 Khan-Uul pilot) is one such platform. Detects 14 high-risk HPV genotypes in pooled form. |
| DE4 | Due for HPV screening | Eligibility outcome: the client meets the criteria to be offered HPV high-risk DNA screening at this encounter. |
| DE5 | Not due — already screened in current cycle | Eligibility outcome: the client is in the target age range, but has had a recent valid HPV screening result and is not due for re-screening at this encounter. |
| DE6 | Excluded — outside target age range | Eligibility outcome: the client is not in the binding target age range (per A/641 section 2.2). For HPV-test-capable facilities, the binding ages are 35 and 45 only. |
| DE7 | Excluded — prior hysterectomy | Eligibility outcome: the client has had a hysterectomy for non-cervical-cancer indication with a documented negative post-operative vaginal-smear cytology, and is therefore exempt from cervical cancer screening per A/641 section 2.2. |
| DE8 | HPV high-risk positive | Result: at least one high-risk human papillomavirus genotype detected in the cervical sample. |
| DE9 | HPV high-risk negative | Result: no high-risk human papillomavirus genotypes detected in the cervical sample. |
| DE10 | Lost to follow-up | Service was expected (e.g., follow-up cytology after a positive HPV result) but did not occur because the patient could not be contacted or did not return for care. Generic LTFU reason; specific causes (phone disconnected, distance, declined) may be added as sub-codes in future iterations. |
| DE13 | Cervical cytology test | A laboratory test in which cervical cells are collected, stained (Papanicolaou or liquid-based), and examined microscopically. Used as a primary screening test in cytology-only facilities (per A/641 section 2.2 cytology pathway) and as a follow-up to a positive HPV result (per A/641 Fig 2.4). |
| DE17 | HIV-positive | Client has a documented positive HIV test or active HIV diagnosis. Per WHO Mongolia, women living with HIV are approximately 6× more likely to develop cervical cancer; HIV+ status is a significant risk modifier for screening intensity and follow-up urgency. |
| DE18 | HIV-negative | Client has a documented negative HIV test. |
| DE19 | HIV status unknown | Client's HIV status has not been documented. May warrant offering HIV testing alongside cervical cancer screening. |
| DE20 | Current smoker | Client currently smokes tobacco (any amount, any form). |
| DE21 | Former smoker | Client has smoked tobacco in the past but has quit. |
| DE22 | Never smoker | Client has never smoked tobacco. |
| DE23 | Past screening: HPV high-risk DNA test | Client's most recent prior cervical cancer screening was an HPV high-risk DNA test. |
| DE24 | Past screening: cytology only | Client's most recent prior cervical cancer screening was cytology (Pap smear) only. |
| DE25 | Past screening: VIA (visual inspection with acetic acid) | Client's most recent prior cervical cancer screening was VIA. Note: VIA is used in some low-resource settings; it is not part of the A/641 (2020) Mongolia binding pathway but may appear in client history from prior years or other countries. |
| DE26 | Past screening: normal / negative | Client's most recent prior screening result was normal / negative for cervical pre-cancer or cancer. |
| DE27 | Past screening: abnormal / positive | Client's most recent prior screening result was abnormal / positive (any abnormality — finer classification not captured at this level). |
| DE28 | Past screening: result unknown | Client recalls having been screened but cannot recall the result, or the result is not in available records. |
| DE29 | Cytology: NILM (negative for intraepithelial lesion or malignancy) | Bethesda 2014 NILM. Cytology shows no evidence of pre-cancerous or cancerous change. In the HPV+ pathway this returns the patient to a 1-year repeat HPV cycle per A/641 Fig 2.4. |
| DE30 | Cytology: ASC-US (atypical squamous cells of undetermined significance) | Bethesda 2014 ASC-US. Atypical squamous cells of undetermined significance. Triggers colposcopy referral in the HPV+ pathway per A/641 Fig 2.4. |
| DE31 | Cytology: ASC-H (atypical squamous cells, cannot exclude HSIL) | Bethesda 2014 ASC-H. Atypical squamous cells where high-grade squamous intraepithelial lesion (HSIL) cannot be excluded. Triggers colposcopy referral. |
| DE32 | Cytology: LSIL (low-grade squamous intraepithelial lesion) | Bethesda 2014 LSIL. Low-grade squamous intraepithelial lesion (corresponds to histologic CIN1). Triggers colposcopy referral in the HPV+ pathway. |
| DE33 | Cytology: HSIL (high-grade squamous intraepithelial lesion) | Bethesda 2014 HSIL. High-grade squamous intraepithelial lesion (corresponds to histologic CIN2 or CIN3). Triggers colposcopy referral with priority. |
| DE34 | Route: return to routine screening | Routing decision output: no abnormality detected; return the patient to the routine screening cycle per the binding pathway (HPV at 35/45 or cytology at the 11-age cycle). |
| DE35 | Route: repeat HPV test in 12 months | Routing decision output: HPV+ with negative cytology re-read; repeat the HPV test in 12 months per A/641 Fig 2.4. |
| DE36 | Route: refer to colposcopy | Routing decision output: HPV+ with cytology ≥ ASC-US, OR HPV+ at 12-month recheck; refer to colposcopy per Op.Inst. 5.6. |
| DE37 | Colposcopy | A diagnostic procedure in which the cervix is examined under magnification (typically with acetic acid application) to identify lesions for biopsy. Per A/641 Op.Inst. 5.6. |
| DE38 | Recall: HPV sample result timeout (3 weeks) | Recall trigger: an HPV sample was dispatched to the lab more than 3 weeks ago and no result has been entered into the registry. Per A/641 section 2.3, this triggers a reminder to follow up with the lab and (if the result is in but not yet entered) the entering staff. |
| DE39 | Recall: positive result follow-up timeout (4 weeks) | Recall trigger: a positive screening result was entered into the registry more than 4 weeks ago and no follow-up examination has been recorded. Per A/641 section 2.3, this triggers a reminder to the patient and the obstetrician-gynaecologist. |
| DE40 | Recall: biopsy result timeout (4 weeks) | Recall trigger: a biopsy sample was received at the lab more than 4 weeks ago and no histopathology result has been entered. Per A/641 section 2.3. |
| DE41 | Recall: treatment timeout after positive biopsy (4 weeks) | Recall trigger: a positive biopsy result has been entered for more than 4 weeks and no treatment record exists. Per A/641 section 2.3. |
| DE42 | Recall: cytology slide unread timeout (2 weeks) | Recall trigger: a cytology slide was received at the lab more than 2 weeks ago and no cytologist conclusion has been entered. Per A/641 section 2.3. |
| DE43 | Recall: second reminder (4 weeks after first) | Recall trigger: a first reminder was sent more than 4 weeks ago and the underlying gap remains unresolved. Per A/641 section 2.3 a second reminder should issue. |
| DE44 | Recall: missed scheduled examination | Recall trigger: the patient had a scheduled examination that they did not attend. Per A/641 section 2.3, immediate flag — does not wait for a timeout. |
| DE45 | Hysterectomy | Surgical removal of the uterus. The cervical-cancer-screening exclusion in A/641 section 2.2 applies only when the hysterectomy was for a non-cervical-cancer indication and the post-operative vaginal-smear cytology was negative. |